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Introduction
Polycythemia vera (PV), essential thrombocythemia (ET),
and primary myelofibrosis (PMF) are clonal hematopoietic
stem cell disorders, characterized by increased proliferation of
terminally differentiated myeloid cells. They have been
recently categorized as classic Philadelphia chromosome-neg-
ative myeloproliferative neoplasms (MPNs) by the WHO
classification of 2008.1 
In spite of PV, ET and PMF being stem-cell derived clonal
diseases, their clonal architecture and hierarchy is complex
and not always predictable.2 The disease course is generally
chronic, but some patients show an inherent tendency for
transformation into acute leukemia, a major complication
with a poor prognosis which is hypothesized to be accompa-
nied by the acquisition of additional genomic lesions.3
Currently known MPN associated mutations involve JAK2,4
MPL,5 TET2,6 ASXL1,7 IDH1, IDH2,8 CBL,9 IKZF1,10 LNK,11
and EZH2.12 Most of these mutations originate at the progen-
itor cell level but they do not necessarily represent the pri-
mary clonogenic event and are not mutually exclusive.2
Interestingly, most of the genes mutated in MPNs are genes
involved in the regulation of different epigenetic mechanisms.
As the epigenetic machinery is one of the main targets of
genetic changes in MPNs, it can be hypothesized that the
epigenome is altered in these neoplasms. Unlike DNA muta-
tions, which are irreversible changes in the DNA sequence
that can result in gene activation or inactivation, epigenetic
changes are defined as reversible modifications that affect
gene expression without altering the DNA sequence itself.13
Among all the epigenetic mechanisms, DNA methylation is
probably the best characterized. It occurs in cytosines fol-
lowed by guanines (CpG) and its role in gene regulation is
well known.14 Aberrant DNA methylation patterning has
been extensively described during oncogenesis, with the gain
of methylation in certain tumor suppressor genes (which
would result in gene inactivation) and loss of methylation in
some other proto-oncogenic genes. DNA methylation
changes have been frequently described in various subtypes
of hematologic neoplasms.15,16 Aberrant DNA methylation
profile is also frequent in myeloid malignancies, particularly
in myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML).17 
Regardless of the recent advances in MPN diagnosis and
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Most DNA methylation studies in classic Philadelphia-negative myeloproliferative neoplasms have been per-
formed on a gene-by-gene basis. Therefore, a more comprehensive methylation profiling is needed to study the
implications of this epigenetic marker in myeloproliferative neoplasms. Here, we have analyzed 71 chronic (24
polycythemia vera, 23 essential thrombocythemia and 24 primary myelofibrosis) and 13 transformed myelopro-
liferative neoplasms using genome-wide DNA methylation arrays. The three types of chronic Philadelphia-nega-
tive myeloproliferative neoplasms showed a similar aberrant DNA methylation pattern when compared to control
samples. Differentially methylated regions were enriched in a gene network centered on the NF-κB pathway, indi-
cating that they may be involved in the pathogenesis of these diseases. In the case of transformed myeloprolifer-
ative neoplasms, we detected an increased number of differentially methylated regions with respect to chronic
myeloproliferative neoplasms. Interestingly, these genes were enriched in a list of differentially methylated regions
in primary acute myeloid leukemia and in a gene network centered around the IFN pathway. Our results suggest
that alterations in the DNA methylation landscape play an important role in the pathogenesis and leukemic trans-
formation of myeloproliferative neoplasms. The therapeutic modulation of epigenetically-deregulated pathways
may allow us to design targeted therapies for these patients.
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ABSTRACT
description of new molecular markers, very little is known
about the molecular mechanisms involved in the patho-
genesis of MPNs and their leukemia transformation. The
identification of new markers for diagnosis and prognosis
is needed to identify best molecular targets for therapy.
There are currently no epigenetic biomarkers in wide-
spread clinical use and most epigenetic studies in MPNs
have focused on the analysis of a few tumor suppressor
genes.16 Therefore, the present study was designed to
establish a global DNA methylation profiling of PV, ET
and PMF.
Methods 
Samples and gene mutation analysis
Bone marrow (BM) aspirates and peripheral blood (PB) samples
(n=71) were collected from patients diagnosed with PV (n=24), ET
(n=23) or PMF (n=24). For this study we also included samples of
4 patients with PV, 4 patients with ET, and 5 patients with PMF at
the time in which the disease had transformed to acute myeloid
leukemia (AML). Diagnosis of MPN was made according to the
World Health Organization (WHO) classification system of hema-
tologic malignancies.1 Control samples included BM (n=4) and PB
(n=4) from healthy donors. In all the cases, the DNA was isolated
from unselected cells. Human samples were drawn after informed
consent had been obtained from the patient or the patient’s
guardians in accordance with the Declaration of Helsinki. This
study was approved by the Research Ethics Committee at the
University of Navarra, Spain. Samples were analyzed for detection
of JAK2V617F mutations by ARMS technique and mutations of
TET2 and EZH2 by direct sequencing as previously described.18 
DNA methylation profiling and analysis 
of microarray data 
The strategy used for DNA methylation profiling and the bioin-
formatics analysis of the DNA methylation data of MPN, MPNs
transformed to acute myeloid leukemia (MPN-AML) and control
samples are described in the Online Supplementary Design and
Methods.
Results
MPN patients and control samples show a distinct DNA
methylation signature 
The methylation profile of samples from patients with
MPNs was compared with the methylation profile of BM
and PB samples from healthy donors. We have previously
shown that BM and PB samples are equivalent in terms of
methylation profile and can thus be combined.18 
Unsupervised hierarchical analysis performed on sam-
ples obtained from healthy donors (n=8) and patients diag-
nosed with MPNs (n=71) showed that most of the MPN
samples clustered together and separated from healthy
controls (Online Supplementary Figure S1). Furthermore,
when we applied the combination of the three different
statistical strategies (t-test, Volcano analysis and methyla-
tion threshold analysis) we found 56 CpGs (corresponding
to 56 unique genes) that showed a consistent differential
DNA methylation between MPNs and control samples
(Figure 1 and Online Supplementary Table S1). Of the 56 dif-
ferentially methylated CpGs, 40 CpG probes (71%) were
hypermethylated in MPNs (including tumor suppressor
genes such as WT1) and from these CpGs, 35 (87.5%)
were located in CpG islands. The remaining 16 CpG
(28.6%) were hypomethylated in MPNs (including
NCOR2 gene, a transcriptional co-repressor protein with
well-established oncogenic roles in prostate or breast can-
cers);19 8 (50%) of them were located in CpG islands.
Using a publicly available methylation dataset from GEO
with accession number GSE41037 (that contains DNA
methylation information from whole blood samples of
394 healthy subjects aged 16-88 years old) we verified that
differential methylation of these 56 CpGs is not due to dif-
ferences in age between our control and MPN sample
groups (data not shown). Analysis of the DNA methylation
levels of two (GAS2 and BHMT) of these 56 genes by
pyrosequencing in a new series of 25 chronic MPN patient
samples and peripheral blood of healthy donor samples,
supports the results obtained in the analysis of the array.
Fifty-six percent of the new sample set analyzed showed
hypomethylation in GAS2, whereas 20% BHMT were
hypermethylated when compared with the control cohort
(Online Supplementary Figure S2). As expected, the results
confirmed what had previously been seen in the methyla-
tion arrays, validating the arrays for further experiments.
To determine whether the three types of MPN analyzed
have a specific profile of DNA methylation, we performed
a new analysis strategy in which each type of MPN was
compared to the control group. The global numbers of dif-
ferentially methylated CpG probes for this analysis were:
91 probes corresponding to 89 different genes in the case
of PV (Online Supplementary Table S2), 25 probes corre-
sponding to 24 genes in the case of ET samples (Online
Supplementary Table S3), and 133 probes corresponding to
122 different genes in the case of PMF samples (Online
Supplementary Table S4). Again, the differentially methylat-
ed CpG probes were predominantly hypermethylated in
all neoplasms studied. There were fourteen common
genes differentially methylated in the three neoplasms
when compared with controls (Online Supplementary Figure
S3A and Online Supplementary Table S5). Interestingly,
when we performed the cluster analysis with the common
(14 genes, Online Supplementary Figure S3B) and uncom-
mon (107 genes: 32 in PV, 4 in ET and 71 in PMF, Online
Supplementary Table S6 and Online Supplementary Figure
S3C) genes, we did not find a specific DNA methylation
profile for each different malignancy. Moreover, the indi-
vidual comparisons between the three disease entities
revealed 12 CpGs differentially methylated between PV
and PMF, 22 CpGs between ET and PV, and 61 between
PMF and ET. These differences were not sufficient to lead
to disease clustering in an unsupervised analysis, confirm-
ing the similarity between MPN subgroups in terms of
DNA methylation levels (Online Supplementary Figure S4). 
Taken together, these results suggest that PV, ET and
PMF have a distinct DNA methylation profile compared to
control samples and are very similar between them, and
that this is true when comparing all the neoplasms togeth-
er against the controls as well as each neoplasm against
the control group. Furthermore, most of the differentially
methylated genes are hypermethylated and map to CpG
islands (72% in PV, 86% in ET, 83% in PMF).
Differentially methylated genes in MPNs are implicated
in specific biological pathways
As shown in the Venn diagram in Online Supplementary
Figure S3, a total of 164 genes were differentially methy-
lated in PV, ET and PMF with respect to control samples.
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Ingenuity pathway analysis of these genes identified a par-
ticular gene network of interest: cell-to-cell signaling and
interaction, hematologic system development and func-
tion, immune cell, involving NF-κB complex (Online
Supplementary Figure S5). NF-κB has been identified as a
key mediator of inflammation-induced carcinogenesis and
the development of progressive myeloproliferative dis-
eases.20 Our study identifies some genes known to indi-
rectly activate NF-κB such as CLEC7A21 or EDARDD,22
both hypomethylated, and others that are involved in
apoptosis and cancer progression, like NCOR2
(hypomethyalted, up-regulated in some cancers)19 or
FASLG (which triggers apoptosis if hypermethylated).23
Ingenuity functional analysis revealed a set of 37 genes
(P=3.22E-05 to 1.48E-02) associated with inflammatory
disease, among which we can find RUNX3, which is
hypermethylated, and known to be preventive for bowel
inflammatory disease,24 or IL3 which is hypomethylated
and associated with inflammatory responses.25 Gene
ontology (GO) analysis showed no enrichment of any
interesting biological function. The bioinformatic analysis
of transcription factor binding sites revealed that differen-
tially methylated genes in chronic MPNs were significant-
ly enriched in GATA1, SP1 and other transcription factors
that play important roles in normal and malignant
hematopoiesis (Online Supplementary Table S7). 
Currently known MPN associated mutations involve
some important epigenetic enzymes, like JAK2, TET2 and
EZH2. Therefore, we hypothesized that mutations in
those genes could be implicated in some of the epigenetic
deregulation observed in chronic MPNs. The distribution
of MPN samples and mutations analyzed in JAK2, TET2
and EZH2 genes is detailed in Online Supplementary Table
S8. The clustering analysis (Figure 1) and supervised analy-
sis between chronic MPNs with JAK2 mutated in
homozygous state and chronic MPNs with wild-type
JAK2 (data not shown) revealed no clear relationship
between JAK2 mutations and the DNA methylation pro-
file. On the other hand, differences in methylation of the
JAK2 promoter were not related to the differential DNA
methylation patterns observed in patients with chronic
MPNs. A b value between 0.3 and 0.7 was found in 7
healthy donor samples and 37 MPN samples, a b value
over 0.7 in 5 MPNs, and 29 MPN samples with a methy-
lation b value below 0.3. TET2 (studied in all chronic MPN
samples) and EZH2 (only analyzed in chronic PMF sam-
ples) were found to be mutated in a very low number of
chronic MPN patients in our sample cohort, precluding
any further meaningful analysis. 
Methylation profiling of MPNs transformed into AML
shows higher levels of methylation than MPNs in
chronic phase
The role of DNA methylation in leukemic transforma-
tion was assessed by comparing the methylation profile of
13 MPNs that had transformed into AML with the 71
C. Pérez et al.
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Figure 1. Hierarchical cluster analysis based on differentially methylated genes in MPNs samples in comparison with healthy donor samples.
b values are depicted using a pseudocolor scale. Red: hypermethylated genes; Green: unmethylated genes. The top bar beneath the dendro-
gram indicates PV, ET, PMF sample type in a specific color-code. Second bar indicates MPNs and healthy donor samples. Third bar indicates









chronic MPNs. Samples were obtained at the time of
transformation.
An unsupervised hierarchical correlation cluster analysis
was performed using all the probes on the array (except
those located on sex chromosomes), including trans-
formed MPNs, chronic MPNs and control samples (Online
Supplementary Figure S6). Subsequently, to investigate the
differences between MPNs and their leukemic transforma-
tion we used a combination of two different strategies: t-
test and volcano analysis. Due to the small number of
samples in transformation, in this analysis we do not use
the methylation threshold analysis. We found 172 differ-
entially methylated CpGs corresponding to 159 unique
genes between chronic phase MPNs and their transformed
state MPN samples (Figure 2 and Online Supplementary
Table S9). Although GSEA analysis revealed that differen-
tially methylated genes in chronic MPN were significantly
enriched (P<0.001) among this gene set (Online
Supplementary Figure S7A), transformed MPN included a
larger number of differentially methylated genes. A total
of 165 CpG probes (96%) where hypermethylated in
transformed MPNs, and from these CpGs, 73 (44%) were
located in CpG islands. In contrast, only 7 CpG probes
(4%) were hypomethylated in MPNs (including genes like
TM4SF1, which encodes for a cell surface antigen and is
highly expressed in different carcinomas).26 Only 2 (29%)
of them were located in CpG islands.
Next, independent comparisons of each type of chronic
DNA methylation in chronic and transformed MPNs
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Figure 2. Hierarchical cluster analysis based on differentially methylated genes in MPNs samples transformed to acute leukemia in compar-
ison with MPNs in chronic phase. b values are depicted using a pseudocolor scale. Red: hypermethylated genes; Green: hypomethylated
genes. The top bar beneath the dendrogram depicts control samples, PV, ET, PMF samples or their transformed state in a specific color-code.
Second bar indicates controls, chronic MPNs or transformed MPN samples.  
Controls Essential thrombocythemia
Transformed essential thrombocythemia Transformed polycythemia vera Transformed primary myelofibrosis
Transformed MPs
Polycythemia vera Primary myelofibrosis
Chronic MPNsControls
MPN with its transformed phase (e.g. samples of chronic
PV with respect to PV samples in transformation phase)
were made using the two above-mentioned strategies.
The overall numbers of differentially methylated CpG
probes for this analysis were 373 probes corresponding to
353 different genes in the case of transformed PV samples
(Online Supplementary Table S10), 419 probes correspon-
ding to 380 different genes in the case of transformed ET
samples (Online Supplementary Table S11), and 58 probes
corresponding to 56 different genes in the case of trans-
formed PMF samples (Online Supplementary Table S12).
The differentially methylated probes were again predom-
inantly hypermethylated and mapped to CpG islands in
all transformed neoplasms studied.
We found 18 common genes differentially methylated
in the transformed MPNs when compared with the chron-
ic phase (Online Supplementary Figure S8A and Online
Supplementary Table S13). Interestingly, when we per-
formed the cluster analysis with the common (18 genes,
Online Supplementary Figure S8B) and uncommon (463
genes, Online Supplementary Table S14 and Online
Supplementary Figure S8B and C, respectively) genes, we
did find a specific DNA methylation profile distinguishing
the transformed and the chronic phase of the disease.
However, the methylation differences between the differ-
ent subtypes of MPNs transformed into AML were subtle,
and the MPN subtypes transformed into AML were clus-
tered together. 
When we compared the methylation profile of the
transformed MPN with publicly available methylation
data from a total of 89 cytogenetically normal AML (CN-
AML) samples27 we found a statistically significant enrich-
ment of genes differentially methylated in the trans-
formed MPNs among the gene set of differentially methy-
lated genes in samples from patients with primary acute
myeloid leukemia (Online Supplementary Figure S7B).
Differentially methylated genes in transformed MPNs
are implicated in specific biological pathways
A total of 628 different genes (corresponding to 862 dif-
ferent CpG probes, coming from both the hierarchical
cluster and the Venn diagram representations, Online
Supplementary Figure S8) that were differentially methylat-
ed between transformed and chronic MPNs were included
in the analysis. Ingenuity pathway analysis of these genes
revealed a particular gene network of interest: cell-to-cell
signaling and interaction, hematologic system develop-
ment and function, and inflammatory response (Online
Supplementary Figure S9). Functional analysis showed that
64 genes were involved in inflammatory response
(P=3.72E-10 to 9.34E-03) and 47 in immunological disease
(P=7.81E-07 to 7.98E-03). Among the genes that are
involved in these networks and those two functional
routes we found two cytokines, IL23 and IL27 (both
hypermethylated in our dataset). IL23 has potent anti-
tumor and anti-metastatic effects28 and is known to induce
the production of IFN gamma.29 In the same way, IL27 has
been shown to induce the expression of IFN gamma,
which in turn modulates the expression of other mole-
cules involved in the inhibition of tumor growth and
metastasis.30 We also found hypermethylated AIM2 which
is thought to mediate reduction of cell proliferation by cell
cycle arrest in some types of cancer.31
Gene ontology analysis showed that genes differentially
methylated between transformed and chronic phases of
MPNs are implicated in immune and inflammatory
response, negative regulation of development process,
negative regulation of lymphocyte activation, negative
regulation of mononuclear cell proliferation, negative reg-
ulation of T-cell proliferation, positive regulation of cellu-
lar process, regulation of cell differentiation, and regula-
tion of leukocyte proliferation. The bioinformatic analysis
of transcription factor binding sites revealed that differen-
tially methylated genes in transformed MPNs with respect
to chronic MPNs were significantly enriched in LMO2,
LEF1 and other transcription factors that play important
roles in normal and malignant hematopoiesis (Online
Supplementary Table S7).
Discussion
Myeloproliferative neoplasms are clonal malignant dis-
eases that arise from the transformation of hematopoietic
stem cells/progenitors (HSCs/HPs) and are characterized
by overproduction of mature erythrocytes, granulocytes
and megakaryocytes. A single point mutation in the tyro-
sine kinase JAK2 (JAK2V617F), present in approximately
95% of patients with PV and 50-60% of patients with ET
and PMF, is considered to be an important driver of these
diseases and has become a formal component of diagnos-
tic criteria. However, this mutation does not explain the
differences between MPNs, indicating that initiation event
or phenotypic differences between these three hematolog-
ic diseases could be influenced by additional unknown
factors.2
Because several genes involved in the regulation of epi-
genetic mechanisms have been described as being altered
in MPNs, we hypothesized that MPN might show differ-
ences in the epigenetic landscape (in terms of DNA
methylation) both at diagnosis and after their transforma-
tion to acute leukemia. The main findings of our study
suggest that abnormal methylation profile is not particu-
larly prevalent in MPN and only during transformation to
acute leukemia are significant changes in the methylation
profile observed. This is consistent with other studies that
indicate that disease progression is associated with abnor-
mal methylation.32-34 Unlike the previous study by Barrio et
al.,35 we found some differences in the methylation profile
between MPNs and healthy donor samples consistent
with a recent work36 that also reported a significant num-
ber of aberrantly methylated genes in MPNs. On the other
hand, we did not find a differential methylation pattern
between PMF and PV/ET. Some of these differences may
be due to differences in sample collection, array coverage
and design or data analysis. A current limitation of our
study was the use of unfractionated BM or PB that may
skew the results of DNA methylation. As clonal involve-
ment both of the myeloid as well as the lymphoid lineage
have been clearly demonstrated in MPNs, we believe that
the use of unfractionated BM or PB samples is suitable to
analyze DNA methylation. Nevertheless, confirmatory
studies using unfractionated samples and preferably puri-
fied cells could be useful to clarify the validity of this
approach.
Regarding the involvement of genes implicated in regu-
lation of epigenetic mechanisms, in our study JAK2 muta-
tional analysis did not show a clear influence in the DNA
methylation profile and the limited sample number of
chronic MPN patients with TET2 or EZH2 lesions preclud-
ed any further analysis. However, as has been shown,
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other mutations such as ASXL1 could influence the DNA
methylation profile of these MPN diseases.36 Whether
studies including larger sets of samples and complete
methylome analysis would be able to implicate inappro-
priate DNA methylation in the pathogenesis of MPNs
remains uncertain. Although the number of differentially
methylated genes reported in our study is low compared
with other hematologic malignancies, such as acute lym-
phoblastic leukemia,37,38 or other MPNs, such as CMML,18
our results indicate that aberrant DNA methylation may
contribute to the pathogenesis of classic Philadelphia chro-
mosome-negative MPNs mainly in the transformation to
acute leukemia.
Despite the limited number of DMR found in MPN, our
results suggest that aberrantly methylated genes in MPNs
are involved in important signal transduction pathways
such as NF-κB associated networks (Online Supplementary
Figure S5). This was not only indicated by the ingenuity
pathway analysis of our samples but was also supported
when we applied the same analysis to publicly available
expression data39 (P=3.02E-02). Deregulation of NF-κB sig-
naling cascade has been described in myeloid and lym-
phoid neoplasias, correlating its degree of activation with
the risk of progression from MDS to AML.40 Beside the
NF-κB pathway, in agreement with a recent report,36 in our
methylated genes data set we found an enrichment of
binding sites for transcription factors such as GATA1 or
SP1 that are altered in hematologic malignancies.41 These
results suggest that the inappropriate methylation of
CpGs may prevent proper binding of these transcription
factors, indirectly altering their participation in the tran-
scription of necessary genes.
Differences in networks affected by aberrant methyla-
tion between chronic phase and transformed MPNs were
clearly identified,  the INF pathway being one of them.
IFNs are normally present at low levels in plasma, which
presumably plays an antiviral and antitumor surveillance
role.42,43 IFN promotes apoptosis of a variety of tumor cell
types44,45 and it has anti-angiogenic properties.44,46 Hence,
this network could be deregulated since several genes
related to IFN are hypermethylated like IL2328 and IL27,47
which could contribute to the pathogenesis of trans-
formed MPNs. It is interesting that IFN has been used with
considerable success in PV, with normalization of blood
counts and achievement of molecular remission in many
cases.44 Moreover, GO analysis showed that these genes
were implicated in the immune and inflammatory
response. This observation is in accordance with the fact
that MPNs are characterized by a state of chronic inflam-
mation, proposed as the common denominator for the
clinical evolution and secondary cancer in patients with
MPNs.48 Transcription factors such as LMO2 were also
identified as aberrantly methylated in transformed sam-
ples.49
In conclusion, our results indicate that: 1) the three types
of MPNs analyzed in our study show a distinct DNA
methylation signature from healthy donors, but the same
pattern of aberrant DNA methylation among pathologies,
and, therefore, changes in DNA methylation, can not
explain the differences in phenotype of these three enti-
ties; 2) genes differentially methylated in MPNs could be
involved in the pathogenesis of these diseases, for exam-
ple, by deregulating the NF-κB pathway; 3) MPNs trans-
formed to acute leukemia have an increased number of
differentially methylated genes compared to MPNs in
chronic phase, and these genes overlap with those seen in
primary AML; and 4) differential DNA methylation of IFN
pathway genes may play a role in disease progression.
Functional studies will be required to clarify the role of
DNA methylation in the deregulation of these pathways
in MPNs to determine if targeting of these pathways or
the use of epigenetic drugs may help prevent disease pro-
gression.
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